Nidor Pty Ltd
Overview
Nidor Pty Ltd was established in 2002 to develop and commercialise non-invasive techniques for assessing the health and function of the gastrointestinal tract.
13C SBT Technology
Nidor's first target area is the small intestine.
In 2003 Nidor secured rights to commercialise a stable isotope 13C breath test (13C SBT) originally devised by the Centre of Paediatric and Adolescent Gastroenterology at the Women's & Children's Hospital, Adelaide, and by the University of Adelaide.
The 13C SBT allows researchers, product developers and clinicians to assess small intestinal function in health and disease. To date this has been difficult in both animals and humans. Current techniques, such as small bowel biopsies, are invasive, expensive, uncomfortable for patients and open to sampling bias. In contrast the 13C SBT is easy to use, safe, non-invasive, repeatable and gives quantitative data.
The test can be applied to animals and humans.
Nidor has demonstrated:
- a normal range for the 13C SBT
- the ability of the 13C SBT to detect and quantify damage to the small intestine resulting from a wide range of chemotherapy agents
- the ability of the 13C SBT to assess protection and repair associated with small intestinal therapeutics
Nidor has developed its GasPACK 13C SBT breath test kit for clinical use. The test is included on the Australian Register of Therapeutic Goods. Discussions are continuing to secure regulatory approval for the test in the USA and EU.
RET Technology
Nidor's next target is the whole gastrointestinal tract.
Nidor is developing a regional enteropathy test (RET), which combines the 13C SBT technology with data from other stable isotope sugars to differentiate damage in the various regions of the gut.
APPLICATIONS
Both the 13C SBT and the RET have product development and clinical applications.
Product Development Applications
The 13C SBT and the RET can be used:
- to assess the gastrointestinal safety of formulations in pre-clinical and early phase trials
- to assess the efficacy of therapeutics intended to benefit the gut
- as a screening tool for all clinical trials where the gastrointestinal health of participating subjects needs to be known
Clinical Applications
The 13C SBT and the RET could be used for:
- detection of gastrointestinal damage associated with cancer treatments (gastrointestinal mucositis)
- monitoring the gastrointestinal health of HIV/AIDS patients (study in progress)
- monitoring the gastrointestinal health of ICU patients (study in progress)
- monitoring for gut damage in gastroenteritis
- diagnosis of inflammatory bowel disease and irritable bowel syndrome
- monitoring of Coeliac disease
- screening long-term NSAID users for gut damage
- as a general practice diagnostic to assist primary health care providers diagnose and treat patients with gastrointestinal complaints
Main business focus/
Listing by sector:
- Medical Devices - In vitro diagnostic devices (IVD)
- Clinical Trials
- Diagnostics
- Nutraceuticals
Competitive Advantages
Nidor has
Corporate Alliances/Partnerships
- Nestec (part of the Nestle group of companies)
- Amgen
- QOL Medical
- The Harvest Plus Foundation
- The Women's & Children's Hospital, Adelaide
- The Royal Adelaide Hospital
- AusIndustry
- Bio Innovation SA
Contact Details
| Contact person | Chris Booton |
|---|---|
| Job Title | Managing Director |
| Address | 53 Erica Avenue |
| City/Suburb | Glen Iris |
| State | Victoria |
| cbooton@nidor.com.au | |
| Phone | +61 (3) 8804 1739 |
| Website | http://www.nidor.com.au |
